Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.61 |
| ▸ | HTR2C | P28335 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13648739 | 0.93 | DRD2 (0.65) | DRD2HTR2CHTR2ADRD4ADRA1A | |
| SCHEMBL7801405 | 0.93 | DRD2 (0.55) | DRD2HTR2CHTR2ADRD4ADRA1A | |
| Ammonia Solution, Strong SCHEMBL2320933 | 0.92 | DRD2 (0.64) | DRD2HTR2CHTR2ADRD4ADRA1A | |
| SCHEMBL1779199 | 0.86 | DRD2 (0.62) | DRD2HTR2CHTR2ADRD4ADRA1A | |
| SCHEMBL4915560 | 0.86 | DRD2 (0.59) | DRD2HTR2CHTR2ADRD4ADRA1A | |
| SCHEMBL13698459 | 0.86 | DRD2 (0.60) | DRD2DRD4ADRA1ADRD3ADRA1B | |
| SCHEMBL4915562 | 0.86 | DRD2 (0.59) | DRD2HTR2CHTR2ADRD4ADRA1A | |
| SCHEMBL7776926 | 0.85 | ADRA1A (0.67) | DRD2ADRA1ADRD3HTR1AADRA1B | |
| SCHEMBL1777570 | 0.85 | DRD2 (0.55) | DRD2HTR2CHTR2ADRD4ADRA1A | |
| SCHEMBL12962316 | 0.84 | HTR1A (0.56) | DRD2HTR2CHTR2ADRD4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | DRD2 506/4885HTR2C 225/4885HTR2A 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.